PEO1 Cell Line
Invented by Simon Langdon at Cancer Research UK Edinburgh Centre
Catalogue Number | 151784 |
Antigen/Gene or Protein Targets | Human ovarian cancer; oestrogen receptor, drug resistance, cisplatin resistance |
Parental Line | PEO1 |
Host | Human |
Tissue | Ovary |
Disease Keywords | Adenocarcinoma |
Model | Tumour line |
Relevance | The PEO1-CDDP Cell Line is an in-vitro model to understand the changes in EGF signalling after the onset of cisplatin resistance. Coupled with this change in drug sensitivity, this model also has a modified responsiveness to ligands of the erbB receptor family. This model will be helpful in studying the changes in cellular signalling after drug treatment, which are currently attracting a great deal of interest and this model will be of particular relevance when cytotoxic therapy is combined with signalling inhibitors. |
Production Details | The PE01CDDP cell line was established by in vitro exposure of the PE01 line to cisplatin commencing at 25 nmol/L cisplatin and increasing to 1 Amol/L over a period of 4 months. The resistant cell line thus obtained was then passaged in the absence of cisplatin for a further 4 months to ensure that the resistance remained stable. PEO1 CDDP is from the same patient as the PEO1, PEO4 and PEO6 cell lines (ECACC Catalogue numbers 10032308, 10032309 & 10032310). |
Research Area | Cancer, Cell Signaling & Signal Transduction, Drug Discovery & Development |
Recommended Growing Conditions | RPMI 1640 containing 10% heat-inactivated FCS, penicillin (100 units/mL), and streptomycin (100 ug/mL). Cells were maintained routinely at 37oC in a humidified atmosphere of 5% CO2 in air. |
Notes | Cisplatin Resistance |
Cellosaurus ID | CVCL_Y032 |
Macleod et al. 2005. Cancer Res. 65(15):6789-800. PMID: 16061661.
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.
Europe PMC ID: 16061661
Macleod et al. 2005. Cancer Res. 65(15):6789-800. PMID: 16061661.
Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.